Optimal management of women with breast cancer is one of the most challenging problems facing oncologists today. Beyond clinical trials, efforts have been made to establish laboratory parameters and to develop test systems to provide information on prognosis and response to therapy, for the optimization of treatment. To date, determination of hormone (oestrogen, progesterone) receptor levels has proved useful in predicting response of individual patients to hormone treatment (Osborne et al., 1980; Paridaens et al., 1980; Hilf et al., 1980) . After the publication of Salmon et al. (1978) on the "differential sensitivities of human tumour stem cells to anticancer drugs", the capacity to predict the response of individual tumours to a given cytotoxic drug seemed to be more feasible.
Till now, there have been only a few reports in the literature on the use of the human tumour cloning assay (HTCA) for pretherapeutic assessment of the chemosensitivity of breast cancer -most of them reflecting a rather reserved acceptance (Pavelic et al., 1980; Sandbach et al., 1982; Schlag et al., 1982; Benard et al., 1983; Touzet et al., 1983; Jones et al., 1984; .
On the basis of our own results, we attempted to appraise the HTCA for its clinical value in mammary carcinoma. Special emphasis has been placed on the interrelationship of risk factors for Correspondence: Ch. Dittrich 
Materials and methods
Eighty-seven specimens from 74 different patients were sent to our laboratory. About two thirds of these were biopsies and one third originated from effusions.
Sample collection, tumour processing, cultivation and drug testing were performed according to the method of Hamburger & Salmon (1977) with recently described modifications Dittrich et al., 1984) .
Processing of tumour specimens Tumour tissue was disaggregated by mincing with scissors into small pieces. The tissue fragments were then incubated in an enzyme cocktail (0.15% collagenase, type IA, Sigma and 0.015% DNase, type I, Sigma) at 37°C for 1-2 h. At completion of the enzymatic dissociation procedure the cells were washed, resuspended in McCoy's 5 A medium and pressed through a 25 pm mesh filter. Cell counts and determination of cell viability using the trypan blue dye exclusion method were performed simultaneously in a Neubauer's haemocytometer. (Alberts et al., 1980) of each chosen drug were tested on every tumour. After incubation of drug tests and controls at 37°C in a humidified 5.5% CO2 atmosphere for 1 h -the time chosen for schedule independent and/or chemically and biologically unstable substances -samples were washed twice in medium and cultivated. Those drugs and hormones being schedule dependent and/or chemically and biologically stable were tested by exposing the cells to the drug dilutions for the entire incubation period (Ludwig & Alberts, 1984) .
Culture
Aliquots of cells resuspended in 0.3% agar in enriched CMRL 1066 medium were plated in 35mm petri dishes over an underlayer of 0.5% a'gar in enriched McCoy's 5A medium. The final concentration was 5 x 10o cells per petri dish. After examination for clumps, the petri dishes were incubated in a humidified 5.5% CO2 atmosphere at 37°C for 2 to 3 weeks. Control plates were routinely reexamined to assess the optimal time for study evaluation.
Test evaluation Colonies were defined as aggregates of 40 or more cells originating from a single cell by cell division (Hamburger & Salmon, 1977 Salmon & Buick (1979) were routinely compared with the cytocentrifuge slides made of each original cell suspension for morphologic evaluation and documentation. A nuclear grading system similar to Bloom's histologic grading (Bloom, 1950a,b) was used to obtain data enabling comparison between cytology and histology. Additional methods used for confirming the malignant nature of the cells from the original cell suspensions and from those growing as colonies were chromosome analysis (Trent, 1980) and in a few cases, transmission electron microscopy (Persky et al., 1982) .
Statistical methods
Comparisons between two groups of data which were not distributed normally were done using Wilcoxon tests. For correlation, the Spearman rank correlation was chosen. Frequencies were evaluated by x2 tests.
Results
Forty-nine out of 87 samples (56%) sent to our laboratory were accepted for evaluation. Reasons for exclusion of 38 specimens are detailed in Table  I . Whereas all of the exclusions of body fluids were due to negative cytology, inadequate cell viability (<30% viable cells by the trypan blue exclusion method) was the main reason for biopsies being unsuitable for evaluation. The origin of the test material is described on Table II .
Clonal growth was observed in only 17/49 (35%) of all adequate breast cancer specimens; effusions providing sufficient growth in more than three quarters of cases, and biopsies in only one of four cases. The overall growth of effusions was significantly higher than that of biopsies (P<0.01, x2=10.04). The median colony number of the effusions was 64 and that of the biopsies, 18. The mean cloning efficiency for all tests was 0.0111% (median 0.0092% range: 0.0010%-0.0486%; Table  III) .
With a median of 93%, the cell viability of the effusions (mean: 87%, range: 48-99%) was Although growth occurred more frequently from biopsies attained from advanced tumours, correlation with tumour stage was not significant. Furthermore, no association was found between clonal growth and the corresponding histopathologic grading in our specimens (n = 22).
Regarding menopausal status no significant difference in growth or lack ofgrowth was found between premenopausal (n = 11) and postmenopausal (n = 32) women in our study. In addition, hormone receptor levels of the tumours of 38 patients were determined. There seemed to be a negative relationship between progesterone receptor (PgR) level and growth, but this did not reach statistical significance (P<0.1) (Table IV) .
Colony growth in the HTCA has been discussed as a possible risk factor for survival, at least regarding other malignancies (Mattox & Von Hoff, (Hellman et al., 1982; Kolaric & Roth, 1983; Oka, 1978) are represented by horizontal bars in Figure 1 . (McGuire et al., 1977) . In 9 of 13 established tumour specimens tested against tamoxifen we obtained the relevant hormone receptor levels, which showed an uncharacteristic distribution (Table V) cytotoxic drugs was found in 92% and 100% of the oestrogen receptor (E2R) positive, but only in 12% and 64% of the E2R negative samples (P<0.01).
Comparison between in vitro prediction and clinical course could be made in 6 patients only. In all other cases, the cytotoxic drugs tested were not the same as those given as therapy. In 4/4 cases resistance prediction was correct, and in 2/2 cases sensitivity was accurately predicted.
Discussion
There are enormous discrepancies in most of the scant data on the use of HTCA in breast cancer sensitivity testing. Many of the differences are the result of varying definitions and interpretations of the fundamental notions about the assay system itself. Our results will be discussed relative to those reported in literature.
Even (Kern et al., 1982; Sutherland et al., 1983; Touzet et al., 1982; Sandbach et al., 1982) . The discrepancies in growth obtained by different authors are less surprising when initial 'standardized' materials are compared. Cloning efficiencies may relate to nucleated cells only (Jones et al., 1984; Sutherland et al., 1983;  own results), to viable cells (Bernard et al., 1983; Sandbach et al., 1982) , or even to viable tumour cells (Schlag et al., 1982; Kern et al., 1982 In contrast to several authors who found no correlation between the number of colonies and the E2R level (Sutherland et al., 1983) or between in vitro colony growth and the E2R level (Sandbach et al., 1982; Benard et al., 1983) , we found a negative trend between PAR positive tumours and their growth in culture (P<0.1). The absence of the differentiation product, PAR may be considered an indicator of shorter disease-free survival (Clark et al., 1983) caused by more primitive cancer cells.
Their aggressiveness seems to be reflected by their growth in the double layer agar system.
Additionally, colony growth in vitro has been shown to represent an independent factor indicative of patients' survival (Mattox & Von Hoff, 1980; Durie et al., 1983) . We found no correlation between colony growth in vitro and patients' survival in our study. Both Sutherland et al. (1983) and Benard et al. (1983) found such relations, at least for subgroups of patients.
The original aim of the creation of the HTCA was to develop a tool enabling therapists to predict in vitro sensitivity or resistance of an individual patient's tumours to a cytotoxic drug. We found that 36% of untreated tumours and 13% of pretreated tumours responded to single agent chemotherapy in vitro, assuming a colony kill of 70% or more as sensitive. These numbers correspond well to the overall percentages in patients under the same monochemotherapy in vivo (Figure 1) .
In our study, we did not observe the increase in sensitivity to tamoxifen which had been expected from estimates of hormone receptor concentration (Jakesz et al., In press ). In contrast, we found a numerical increase in tamoxifen-resistant specimens among the E2R positive ones. There are no data indicating that the HTCA is equivalent to the determination of hormone receptor levels for the prediction of tumour sensitivity to hormones. To date, there are insufficient data from which to derive a consensus on the value of hormone receptor determination for the prediction of chemosensitivity in women with breast cancer (Lippmann et al., 1978; Kiang et al., 1978; Dittrich et al., 1980) . The in vitro data of this study demonstrate that positive E2R levels, are correlated with resistance to cytotoxic drugs to a statistically significant degree (P<0.01), thus confirming Lippman's hypothesis of increasing chemosensitivity of E2R negative tumours. These data should be the subject of further studies.
The only parameter for ascertaining the value of an in vitro predictive system is the congruence between accuracy of in vitro prediction and clinical course of patients treated accordingly. Information on this question is scant to date. Sutherland et al. (1983) reported on two correct resistance predictions; Jones et al. (1984) described a total of 59 correlations, 22 thereof having been correct resistance predictions for single agent chemotherapy, and 13 correct resistance predictions for combination chemotherapy. We were able to do 6 in vitro-in vivo correlations; in 4 cases resistance and in 2 cases, sensitivity were correctly predicted.
In our study, we tried to establish correlations between factors inherent in patients with breast cancer, such as tumour size, histopathologic grading, hormone receptor level, menopausal status, chemo-and hormone-sensitivity, as well as survival prognosis on the one hand, and the behaviour of these patients' tumour cells in the soft agar culture on the other. Because of the low overall number of results obtained by this test system at present, any deployment of the HTCA with the intention of evaluating chemo-and hormone-sensitivity or of predicting the prognosis of women with breast cancer must still be considered investigative. Attention must be focussed on improving the test system before the HTCA may be expected to provide further essential information on the management of patients with breast cancer.
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